China Shineway Pharmaceutical Group Ltd. has announced its turnover for the first quarter of 2025, reporting actual results that show a significant decline in sales compared to the same period in 2024. The company's turnover for the three months ended March 31, 2025, amounted to RMB761 million, marking a decrease of 31.9% from the previous year. The breakdown of the turnover reveals that injection products saw a decrease of 35.5%, amounting to RMB262 million. Soft capsule products experienced a substantial drop of 52.9%, with a turnover of RMB81 million. Granule products reported a decrease of 41.2%, reaching RMB117 million, while TCM formula granule products saw a decline of 13.8%, totaling RMB244 million. Products in other forms decreased slightly by 1.7%, with a turnover of RMB57 million. In terms of product mix for the first quarter of 2025, injection products accounted for approximately 34.4% of the total turnover, soft capsule products for 10.6%, granule products for 15.4%, and TCM formula granule products for 32.1%.